FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to novel pyrimidine derivatives of general formula I, as well as to their diastereoisomers, enentiomers and/or pharmaceutically acceptable salts, which possess inhibiting action with respect to cyclin-dependent kinases and/or tyrosinekinases of VEGF receptor. In compound of general formula (I) 
Q stands for group 
where D, E, G, L, M and T in each case represent carbon, R1 represents hydrogen, halogen or CF3, R2 represents C1-C10-alkyl, which can optionally be disrupted with one group-C(O), C2-C10-alkinyl, C3-C10-cycloalkyl or phenyl, which is optionally substituted in one or more places in similar or different way by hydroxyl, halogen, C1-C6-alkoxy, C1-C6-alkyl, C3-C10-cycloalkyl, C1-C6-alkoxy-C1-C6-alkyl, C1-C6-alkoxy-C1-C6-alkoxy-C1-C6-alkyl or -COR8, X represents oxygen, sulphur or group -NH-, R3 represents hydroxy, halogen, CF3 or C1-C6-alkoxy, m represents 0-4, R4 represents hydrogen or group -COR8, NO2 or -SO2R7, or represents C1-C10-alkyl or C3-C10-cycloalkyl, R5 represents C1-C10-alkyl, which can be optionally substituted in one or more places, in similar or different way, by hydroxyl or C3-C10-cycloalkyl, or C3-C10-cycloalkyl, R7 represents C1-C10-alkyl, which is optionally substituted by group trimethylsilanyl (TMS), R8 represents C1-C6-alkyl, C1-C6-alkoxy. Invention also relates to intermediate compounds.
EFFECT: compounds can be applied for obtaining medication intended for treatment of cancer, selected from Kaposhi's sarcoma, Khodgkin's disease, leukemia or solid tumour, such as carcinoma of mammalian gland, kung, large intestine or prostate gland, autoimmune disease, such as psoriasis, and/or proliferative diseases, such as hemangioma or angiofibroma.
21 cl, 3 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OBTAINING DIHYDROTHIENO[3,2-d]PYRIMIDINES AND INTERMEDIATE PRODUCTS, APPLIED FOR THEIR SYNTHESIS | 2008 |
|
RU2528340C2 |
| DEUTERATED BENZYL BENZENE DERIVATES AND METHODS FOR USE | 2009 |
|
RU2509773C2 |
| PRODUCT COMPRISING AT LEAST ONE SUBSTANCE INHIBITING ACTIVITY OF NO-SYNTHASE IN COMBINATION WITH AT LEAST ONE SUBSTANCE INHIBITING ACTIVITY OF PHOSPHOLIPASE A | 2000 |
|
RU2256465C2 |
| SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES AS Rho-KINASE INHIBITORS | 2007 |
|
RU2455302C2 |
| CYCLOALKYLAMINE-SUBSTITUTED ISOQUINOLONE DERIVATIVES | 2007 |
|
RU2457203C2 |
| CYCLOHEXYLAMINIZOQUINOLONE AS Rho-KINASE INHIBITORS | 2006 |
|
RU2440988C2 |
| NOVEL DERIVATIVES OF IMIDAZOLIDINE, THEIR PREPARING AND USING AS VLA-4 ANTAGONIST | 2002 |
|
RU2318815C2 |
| PIPERADINYL-SUBSTITUTED ISOQUINOLONE DERIVATIVES AS Rho-KINASE INHIBITORS | 2006 |
|
RU2414467C2 |
| TRIAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1995 |
|
RU2167869C2 |
| MEK INHIBITORS AND THEIR THERAPEUTIC USE | 2021 |
|
RU2812929C1 |
